Global Access Diagnostics
Global Access Diagnostics (GADx) is a leading developer of lateral flow and rapid diagnostic technologies, products, and services. As a social enterprise, it is dedicated to improving global health by providing innovative, affordable, and accessible diagnostic solutions. GADx collaborates with partners worldwide to develop and manufacture high-quality diagnostics for human, veterinary, and agricultural applications, reinvesting profits into impact-led health programs and local manufacturing initiatives. The company actively engages in international collaborations and projects, including the EU-funded Di-Dida project, to develop cost-effective, mobile-based diagnostic solutions in Africa, aiming to detect multiple diseases simultaneously.
Industries
Nr. of Employees
medium (51-250)
Global Access Diagnostics
Products
COVID-19 rapid antigen self-test (home-use, EUA)
A two-component, user-friendly rapid antigen test for SARS-CoV-2 designed for over-the-counter home use with an integrated buffer and unitized design to simplify testing and reduce biohazard risk. Reported FDA Emergency Use Authorization for home use.
Rapid lateral flow test for Botrytis (on-site plant pathogen detection)
A rapid, on-site lateral flow immunoassay to detect and quantify Botrytis cinerea contamination in grape harvests and horticultural samples to enable vineyard-level decision making.
Rapid Cystatin C kidney function lateral flow test
A rapid lateral flow test to measure cystatin C for assessment of kidney function, developed for integration with a point-of-care testing platform.
Rapid liver fluke diagnostic (development/partnership)
Development collaboration on a rapid diagnostic test for liver fluke to support livestock health and management; project described in recent case study and news items.
IT LEISH rapid diagnostic test (manufacturing rights and relaunch)
Manufacturing rights acquisition and reintroduction of an existing rapid diagnostic test for visceral leishmaniasis intended to increase access and local manufacture.
COVID-19 rapid antigen self-test (home-use, EUA)
A two-component, user-friendly rapid antigen test for SARS-CoV-2 designed for over-the-counter home use with an integrated buffer and unitized design to simplify testing and reduce biohazard risk. Reported FDA Emergency Use Authorization for home use.
Rapid lateral flow test for Botrytis (on-site plant pathogen detection)
A rapid, on-site lateral flow immunoassay to detect and quantify Botrytis cinerea contamination in grape harvests and horticultural samples to enable vineyard-level decision making.
Rapid Cystatin C kidney function lateral flow test
A rapid lateral flow test to measure cystatin C for assessment of kidney function, developed for integration with a point-of-care testing platform.
Rapid liver fluke diagnostic (development/partnership)
Development collaboration on a rapid diagnostic test for liver fluke to support livestock health and management; project described in recent case study and news items.
IT LEISH rapid diagnostic test (manufacturing rights and relaunch)
Manufacturing rights acquisition and reintroduction of an existing rapid diagnostic test for visceral leishmaniasis intended to increase access and local manufacture.
Services
Contract research: assay and device development
End-to-end contract research services for rapid diagnostics including assay design, reagent development, device prototyping, optimisation and stage-gated project delivery.
Reagent development and analytical characterisation
Custom production, purification and analytical testing of antibodies, recombinant proteins, peptides and conjugates with methods to verify identity, purity and activity.
Device prototyping and housing design
Industrial design, rapid prototyping (3D printing) and usability testing for device housings and integrated sample collection systems.
Validation, stability testing and small clinical evaluations
Performance verification, shelf-life stability studies, sample characterisation and facilitation of small-scale clinical evaluations and training sets.
Clinical trial services for medical devices
Protocol and study design, site selection and setup, monitoring, data management, biostatistics, regulatory support and post-market surveillance for device trials.
Technical transfer and local manufacturing support
Process development, documentation, hands-on training and technology transfer to establish or expand local lateral flow manufacturing capacity in partner regions.
Contract research: assay and device development
End-to-end contract research services for rapid diagnostics including assay design, reagent development, device prototyping, optimisation and stage-gated project delivery.
Reagent development and analytical characterisation
Custom production, purification and analytical testing of antibodies, recombinant proteins, peptides and conjugates with methods to verify identity, purity and activity.
Device prototyping and housing design
Industrial design, rapid prototyping (3D printing) and usability testing for device housings and integrated sample collection systems.
Validation, stability testing and small clinical evaluations
Performance verification, shelf-life stability studies, sample characterisation and facilitation of small-scale clinical evaluations and training sets.
Clinical trial services for medical devices
Protocol and study design, site selection and setup, monitoring, data management, biostatistics, regulatory support and post-market surveillance for device trials.
Technical transfer and local manufacturing support
Process development, documentation, hands-on training and technology transfer to establish or expand local lateral flow manufacturing capacity in partner regions.
Expertise Areas
- Lateral flow assay development
- Multiplex diagnostics for infectious and non-communicable diseases
- Antibody engineering and recombinant binders
- Reagent production and analytical characterisation
Key Technologies
- Lateral flow immunoassay (LFIA)
- Multiplex lateral flow assay formats
- Enzyme-activity detection in lateral flow
- Recombinant antibody production